HIT diagnosis
| Variable . | Total patients with HIT suspicions N = 113 . | Patients with non-HIT n = 70 . | Patients with HIT n = 43 . | P value . |
|---|---|---|---|---|
| Heparin therapy at HIT suspicion, n (%) | .5 | |||
| UFH | 69 (61) | 41 (59) | 28 (65) | |
| LMWH | 44 (39) | 29 (41) | 15 (35) | |
| Therapeutic anticoagulation | 75 (71) | 44 (67) | 31 (79) | .2 |
| Prophylactic anticoagulation | 30 (29) | 22 (33) | 8 (21) | |
| Delay after heparin initiation, median [IQR], d | 8.0 [6.0-12.0] | 7.0 [5.2-12.0] | 9.0 [8.0-12.0] | .01 |
| Heparin treatment in the last 3 months | 15 (13) | 12 (17) | 3 (7) | .3 |
| Clinical setting at the time of HIT suspicion, n (%) | ||||
| CABG | 30 (27) | 14 (20) | 16 (37) | .04 |
| ECMO | 9 (8) | 6 (9) | 3 (7) | 1.0 |
| ECMO thrombosis | 1 (1) | 1 (1) | 0 (0) | 1.0 |
| Dialysis | 24 (21) | 17 (24) | 7 (16) | .3 |
| Citrate | 12 (52) | 8 (50) | 4 (57) | |
| Heparin | 11 (48) | 8 (50) | 3 (43) | |
| Dialysis thrombosis | 9 (29) | 5 (21) | 4 (57) | .2 |
| Clinical manifestations at the time of HIT suspicion, n (%) | ||||
| Arterial thrombosis | 13 (12) | 7 (10) | 6 (14) | .6 |
| Extension of arterial thrombosis | 6 (5) | 3 (4) | 3 (7) | .7 |
| Venous thrombosis | 29 (26) | 18 (26) | 11 (26) | 1.0 |
| DVT | 10 (9) | 8 (11) | 2 (5) | .3 |
| PE | 10 (9) | 6 (9) | 4 (9) | 1.0 |
| Extension of preexisting thrombosis | 7 (6) | 4 (6) | 3 (7) | 1.0 |
| Cutaneous effect | 7 (6) | 3 (4) | 4 (9) | .4 |
| Biological examination at the time of HIT suspicion, median [IQR] | ||||
| Platelets (×109/L) | 83 [49-115] | 77 [53-108] | 87 [48-122] | .9 |
| Leukocytes (×109/L) | 11 [8-16] | 10 [7-15] | 13 [10-16] | .02 |
| Hemoglobin (g/L) | 94 [85-109] | 95 [85-109] | 93 [84-106] | .5 |
| PT (%) | 76 [68-85] | 76 [66-85] | 79 [68-86] | .4 |
| Hemoglobin nadir (g/L) | 82 [72-96] | 81 [72-98] | 83 [72-94] | 1.0 |
| Platelet nadir (×109/L) | 55 [34, 88] | 57 [32, 87] | 52 [36, 88] | 1.0 |
| Platelets return to normal, n (%) | 77 (73) | 43 (66) | 34 (85) | .03 |
| Time to normalize platelets (d) | 6 [3-9] | 5 [4-10] | 6 [3-8] | .3 |
| 4Ts score, n (%) | .001 | |||
| 4 and 5 | 89 (79) | 62 (89) | 27 (63) | |
| 6-8 | 24 (21) | 8 (11) | 16 (37) | |
| IgG anti-PF4/H, median [IQR], UI/mL | ||||
| ELISA | 0.60 [0.06-1.74] | 0.07 [0.04-0.49] | 1.88 [1.44-2.39] | <.001 |
| CLIA | 0.74 [0.10-15.72] | 0.13 [0.03-0.71] | 17.6 [4.18-36.9] | <.001 |
| SRA, n (%) | <.001 | |||
| Positive | 42 (66) | 0 (0) | 42 (66) | |
| Negative | 18 (28) | 18 (86) | 0 (0) | |
| Indeterminate | 4 (6) | 3 (14) | 1 (2) | |
| Variable . | Total patients with HIT suspicions N = 113 . | Patients with non-HIT n = 70 . | Patients with HIT n = 43 . | P value . |
|---|---|---|---|---|
| Heparin therapy at HIT suspicion, n (%) | .5 | |||
| UFH | 69 (61) | 41 (59) | 28 (65) | |
| LMWH | 44 (39) | 29 (41) | 15 (35) | |
| Therapeutic anticoagulation | 75 (71) | 44 (67) | 31 (79) | .2 |
| Prophylactic anticoagulation | 30 (29) | 22 (33) | 8 (21) | |
| Delay after heparin initiation, median [IQR], d | 8.0 [6.0-12.0] | 7.0 [5.2-12.0] | 9.0 [8.0-12.0] | .01 |
| Heparin treatment in the last 3 months | 15 (13) | 12 (17) | 3 (7) | .3 |
| Clinical setting at the time of HIT suspicion, n (%) | ||||
| CABG | 30 (27) | 14 (20) | 16 (37) | .04 |
| ECMO | 9 (8) | 6 (9) | 3 (7) | 1.0 |
| ECMO thrombosis | 1 (1) | 1 (1) | 0 (0) | 1.0 |
| Dialysis | 24 (21) | 17 (24) | 7 (16) | .3 |
| Citrate | 12 (52) | 8 (50) | 4 (57) | |
| Heparin | 11 (48) | 8 (50) | 3 (43) | |
| Dialysis thrombosis | 9 (29) | 5 (21) | 4 (57) | .2 |
| Clinical manifestations at the time of HIT suspicion, n (%) | ||||
| Arterial thrombosis | 13 (12) | 7 (10) | 6 (14) | .6 |
| Extension of arterial thrombosis | 6 (5) | 3 (4) | 3 (7) | .7 |
| Venous thrombosis | 29 (26) | 18 (26) | 11 (26) | 1.0 |
| DVT | 10 (9) | 8 (11) | 2 (5) | .3 |
| PE | 10 (9) | 6 (9) | 4 (9) | 1.0 |
| Extension of preexisting thrombosis | 7 (6) | 4 (6) | 3 (7) | 1.0 |
| Cutaneous effect | 7 (6) | 3 (4) | 4 (9) | .4 |
| Biological examination at the time of HIT suspicion, median [IQR] | ||||
| Platelets (×109/L) | 83 [49-115] | 77 [53-108] | 87 [48-122] | .9 |
| Leukocytes (×109/L) | 11 [8-16] | 10 [7-15] | 13 [10-16] | .02 |
| Hemoglobin (g/L) | 94 [85-109] | 95 [85-109] | 93 [84-106] | .5 |
| PT (%) | 76 [68-85] | 76 [66-85] | 79 [68-86] | .4 |
| Hemoglobin nadir (g/L) | 82 [72-96] | 81 [72-98] | 83 [72-94] | 1.0 |
| Platelet nadir (×109/L) | 55 [34, 88] | 57 [32, 87] | 52 [36, 88] | 1.0 |
| Platelets return to normal, n (%) | 77 (73) | 43 (66) | 34 (85) | .03 |
| Time to normalize platelets (d) | 6 [3-9] | 5 [4-10] | 6 [3-8] | .3 |
| 4Ts score, n (%) | .001 | |||
| 4 and 5 | 89 (79) | 62 (89) | 27 (63) | |
| 6-8 | 24 (21) | 8 (11) | 16 (37) | |
| IgG anti-PF4/H, median [IQR], UI/mL | ||||
| ELISA | 0.60 [0.06-1.74] | 0.07 [0.04-0.49] | 1.88 [1.44-2.39] | <.001 |
| CLIA | 0.74 [0.10-15.72] | 0.13 [0.03-0.71] | 17.6 [4.18-36.9] | <.001 |
| SRA, n (%) | <.001 | |||
| Positive | 42 (66) | 0 (0) | 42 (66) | |
| Negative | 18 (28) | 18 (86) | 0 (0) | |
| Indeterminate | 4 (6) | 3 (14) | 1 (2) | |
CABG, coronary artery bypass graft; DVT, deep vein thrombosis; ECMO, extracorporeal membrane oxygenation; LMWH, low-molecular-weight heparin; PE, pulmonary embolism; PT, prothrombin time.
Patients with HIT and non-HIT were compared (P value α = 5%).